EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice

Xiaojie Huang, Guanchao Pang, Zhirong Mao, Baizhou Li, Zhihua Teng, Yan Yang, Zijian Qiu iD, Xiuxiu Chen, Pingli Wang iD

The Clinical Respiratory Journal · 2024

DOI: 10.1111/crj.13761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Xiaojie Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In order to improve survival outcomes in resectable non‐small cell lung cancer (NSCLC), strategies for neoadjuvant therapy need to be revisited. We evaluated and compared the efficacy of different neoadjuvant therapeutic modalities in a real‐world setting.

Methods

A total of 258 patients with clinical stage IIA to IIIB NSCLC was included. All the patients underwent surgical resection after one to four cycles of neoadjuvant treatment consisting of chemotherapy (83), immunotherapy (23), and immunotherapy plus chemotherapy (152).

Results

The radiologic response rate in the combined immunochemotherapy group was 67.8%, higher than that of 48.2% in the chemotherapy group and 4.3% in the immunotherapy group ( p < 0.001). An improved major pathological response (MPR) was also achieved in the combined therapy group compared with the chemotherapy group and the immunotherapy group (53.9% vs. 10.8% vs. 8.7%, p < 0.001). Patients in the combined therapy group had a significant trend toward longer disease‐free survival than those in the chemotherapy alone group (3‐year disease‐free survival [DFS] of 68.79% vs. 50.81%; hazard ratio [HR] for progression or death, 0.477; p = 0.003). Multivariate Cox analysis identified radical surgery (HR, 0.328; p = 0.033), ypN0–1 stage (HR, 0.591; p = 0.038) and MPR result (HR, 0.362; p = 0.007) to be independent prognostic factors for DFS.

Conclusions

Neoadjuvant treatment with a combination of immunotherapy plus chemotherapy appears to achieve higher radiological and pathological responses than monotherapy for IIA‐IIIB NSCLC. Log‐rank analysis showed that a better outcome could be expected in patients with the addition of immunotherapy to neoadjuvant chemotherapy if compared with patients with chemotherapy alone in terms of DFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsImmunotherapyHumansMaleFemaleMiddle AgedAgedNeoplasm StagingTreatment OutcomeRetrospective StudiesPneumonectomyDisease-Free SurvivalAdultAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chemotherapydisease‐free survivalimmunochemotherapyimmunotherapyneoadjuvantnon‐small cell lung cancertreatment response

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
  • Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.
  • Department of Pathology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
  • Department of Thoracic Surgery, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
  • Department of Radiotherapy, Quzhou People's Hospital, Quzhou, China.

ORCID-Profile: Zijian Qiu, Pingli Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, X., Pang, G., Mao, Z., Li, B., Teng, Z., Yang, Y., Qiu, Z., Chen, X., & Wang, P. (2024). Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13761

Vancouver

Huang X, Pang G, Mao Z, Li B, Teng Z, Yang Y, et al. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13761

BibTeX
@article{Huang2024,
  author = {Huang, Xiaojie and Pang, Guanchao and Mao, Zhirong and Li, Baizhou and Teng, Zhihua and Yang, Yan and Qiu, Zijian and Chen, Xiuxiu and Wang, Pingli},
  title = {Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice},
  journal = {The Clinical Respiratory Journal},
  year = {2024},
  doi = {10.1111/crj.13761}
}
Kostenlos starten →